The Worry About Clopidogrel "Nonresponsiveness". Identification and Treatment in the Post-Percutaneous Coronary Intervention Patient

JACC: Cardiovascular Interventions

Volumn 2, Issue 11, 2009, Pages 1102-1104

  Gurbel, Paul A ^a   Tantry, Udaya S ^a   Shuldiner, Alan R ^b  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

clopidogrel; gene polymorphism; nonresponsiveness; platelet

Indexed keywords

ADENOSINE DIPHOSPHATE; CALCIUM ANTAGONIST; CLOPIDOGREL; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTON PUMP INHIBITOR; PURINERGIC P2Y12 RECEPTOR;

CHROMOSOME 10Q; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DOSE RESPONSE; DRUG ACTIVATION; DRUG COMPETITION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; EDITORIAL; GENE MUTATION; HUMAN; LOADING DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STENT THROMBOSIS; THROMBOCYTE AGGREGATION INHIBITION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ARYL HYDROCARBON HYDROXYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; GENE FREQUENCY; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; PHENOTYPE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; TICLOPIDINE; TIME FACTORS;

EID: 70449502989     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2009.09.005     Document Type: Editorial

References (9)

1. Gurbel P.A., Becker R.C., Mann K.G., Steinhubl S.R., and Michelson A.D. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 50 (2007) 1822-1834
2. Gurbel P.A., Antonino M.J., Bliden K.P., et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Platelets 19 (2008) 595-604
3. Kereiakes D.J., and Gurbel P.A. Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention. J Am Coll Cardiol Intv 1 (2008) 111-121
4. Gladding P., White H., Voss J., et al. Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study. J Am Coll Cardiol Intv 2 (2009) 1095-1101
5. Gurbel P.A., Antonino M.J., and Tantry U.S. Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Expert Opin Drug Metab Toxicol 5 (2009) 989-1004
6. Shuldiner A.R., O'Connell J.R., Bliden K.P., et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302 (2009) 849-857
7. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360 (2009) 354-362
8. Mehta SR, on behalf of the CURRENT Investigators. A randomized comparison of a clopidogrel high loading and maintenance dose regimen versus standard dose and high versus low dose aspirin in 25,000 patients with acute coronary syndromes: results of the CURRENT OASIS 7 trial. Presented at: European Society of Cardiology 2009 Congress; August 30, 2009; Barcelona, Spain.
9. Wiviott S.D., Braunwald E., McCabe C.H., et al., TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015